Former FDAer Defends FDA Decision To Withdraw Data Falsification Rule

A former FDA policy adviser believes a recent letter from senators, including two presidential hopefuls, calling for the agency to defend the withdrawal of its data falsification reporting rule, and possibly even revive the rule, is politically motivated, as FDA already determined the rule itself would not result in any practical benefit for public health. One public health advocate, however, argued that had the rule been revised and finalized rather than withdrawn, it could have prevented the recent scandal surrounding...